Scientific article
Open access

IL-17A in psoriasis and beyond: cardiovascular and metabolic implications

Published inFrontiers in Immunology, vol. 10, 3096
Publication date2020

Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and IL-17F, which act on immune and non-immune cell types and strongly contribute to tissue inflammation. In psoriatic lesions, IL-17A, IL-17E, and IL-17F are involved in neutrophil accumulation, followed by the formation of epidermal micro abscesses. IL-17A together with other Th17 cytokines also upregulates the production of several chemokines that are implicated in psoriasis pathogenesis. IL17A-targeting antibodies show an impressive clinical efficacy in patients with psoriasis. Studies have reported an improvement of at least 75% as measured by the psoriasis area and severity index (PASI) in >80% of patients treated with anti-IL-17A therapy. Psoriasis skin manifestations, cardiovascular as well as metabolic disease in psoriasis appear to share pathogenic mechanisms evolving around IL-17A and its proinflammatory role. Thus, anti-IL-17A therapy not only improves skin manifestations of psoriasis, but also cardiovascular inflammation as well as metabolic factors and different domains of psoriatic arthritis (PsA) including peripheral arthritis, enthesitis, dactylitis, and axial involvement. This review summarizes the biological role of IL-17A, before reviewing currently available data on its role in the physiology and pathophysiology of the skin, as well as the cardiovascular and the metabolic system. In conclusion, clinical recommendations for patients with moderate to severe psoriasis based on the current available data are given.

  • Arthritis
  • Psoriatic/immunology/pathology/therapy
  • Cardiovascular Diseases/immunology/pathology/therapy
  • Humans
  • Interleukin-17/antagonists & inhibitors/immunology
  • Metabolic Diseases/immunology/pathology/therapy
  • Th17 Cells/immunology/pathology
Citation (ISO format)
VON STEBUT, Esther et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. In: Frontiers in Immunology, 2020, vol. 10, p. 3096. doi: 10.3389/fimmu.2019.03096
Main files (1)
Article (Published version)
ISSN of the journal1664-3224

Technical informations

Creation04/30/2021 3:18:00 PM
First validation04/30/2021 3:18:00 PM
Update time03/16/2023 1:19:26 AM
Status update03/16/2023 1:19:25 AM
Last indexation02/12/2024 12:10:23 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack